Related Experiment Video
Updated: May 20, 2026
09:33
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Antiangiogenic therapy for glioma
Valentina Cea1, Carlo Sala, Chiara Verpelli
1Department of Pharmacology, CNR Institute of Neuroscience, University of Milan, Via Vanvitelli 32, 20129 Milan, Italy.
Journal of Signal Transduction
|July 26, 2012
Summary
Glioma treatment faces challenges due to abnormal tumor vasculature and cell invasion, leading to therapeutic resistance. Further research into molecular mechanisms of angiogenesis and invasion is crucial for developing curative therapies.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Molecular Medicine
Background:
- Antiangiogenic agents are standard glioma treatment.
- Despite therapies, glioma remains incurable.
- Tumor vasculature and cell invasion drive therapeutic resistance.
Purpose of the Study:
- Review molecular mechanisms of angiogenesis and invasion in malignant glioma.
- Present current and potential antiangiogenic drugs for glioma.
- Identify mediators of resistance to antiangiogenic therapy.
Main Methods:
- Literature review of molecular mechanisms.
- Analysis of antiangiogenic drug efficacy.
- Focus on key mediators of therapeutic resistance.
Main Results:
- Malignant glioma exhibits complex angiogenesis and invasion.
- Several antiangiogenic drugs show potential.
- Key molecular mediators of resistance identified.
Conclusions:
- Understanding angiogenesis and invasion is vital for glioma treatment.
- Targeting resistance mechanisms may improve outcomes.
- Further research needed for curative glioma therapies.
